A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against *Clostridium difficile* infection in mice and hamsters

Yuan-kai Wang1,2, Ya-xian Yan2, Hyeun Bum Kim1,3, Xianghong Ju1, Song Zhao1, Keshan Zhang1, Saul Tzipori1, and Xingmin Sun1,4,*

1Department of Infectious Diseases and Global Health; Tufts University Cummings School of Veterinary Medicine; North Grafton, MA USA; 2School of Agriculture and Biology; Shanghai Jiao Tong University; Shanghai Key Laboratory of Veterinary Biotechnology; Key Laboratory of Urban Agriculture (South) Ministry of Agriculture; Shanghai, PR China; 3Department of Animal Resource and Science; Dankook University; Cheonan, Choongnam, South Korea; 4Clinical and Translational Science Institute; Tufts University; Boston, MA USA

**Keywords:** chimeric protein, *Clostridium difficile* infection, vaccine

*Clostridium difficile* is the major cause of hospital-acquired infectious diarrhea and colitis in developed countries. The pathogenicity of *C. difficile* is mainly mediated by the release of 2 large potent exotoxins, toxin A (TcdA) and toxin B (TcdB), both of which require neutralization to prevent disease occurrence. We have generated a novel chimeric protein, designated mTcd138, comprised of the glucosyltransferase and cysteine proteinase domains of TcdB and the receptor binding domain of TcdA and expressed it in *Bacillus megaterium*. To ensure that mTcd138 is atoxic, 2 point mutations were introduced to the glucosyltransferase domain of TcdB, which essentially eliminates toxicity of mTcd138. Parenteral immunizations of mice and hamsters with mTcd138 induced protective antibodies to both toxins and provided protection against infection with the hyper-virulent *C. difficile* strain UK6.

**Introduction**

*Clostridium difficile* is the most common cause of antibiotic-associated diarrhea in hospitalized patients in the developed world. Since 2005, *C. difficile* infection (CDI) has been increasingly reported among young and healthy individuals. Today, CDI is a huge social and economic burden causing an estimated $3.2 billion of health care cost to US hospitals alone.2,3

Advanced age (≥65 years), antibiotic use, immunosuppression, exposure to health care system and long-time hospitalization are major risk factors for CDI.4 *C. difficile* toxins A (TcdA) and B (TcdB) are the major virulence factors. Both toxins share similar domain structures, including the N-terminal glucosyltransferase domain (GT), the autocatalytic cysteine proteinase domain (CPD), the central translocation domain (TMD), and the C-terminal receptor binding domain (RBD).5,6

Currently, standard treatment of severe CDI is the use of vancomycin, metronidazole or fidaxomicin.7-9 While effective, these antibiotics may contribute to a very high recurrence rate ranging from 20–35%.10,11 A recent computer simulation shows that vaccination could be the cost-effective approach in the prevention and treatment of CDI, especially the recurrent CDI.12

It was initially reported that anti-TcdA antibodies were sufficient to protect the host against CDI.13,14 However, recent studies demonstrated an even more important role of TcdB in the pathogenesis of CDI,15-18 suggesting that an effective vaccine should target both toxins.

Vaccines targeting the *C. difficile* toxins include toxoids and toxin fragments.24-29 Formaldehyde-inactivated native *C. difficile* toxoid is a candidate for the first cytotoxic T lymphocyte response induction vaccine against CDI.30 This study demonstrates the potential of a novel chimeric protein vaccine against *C. difficile* infection in mice and hamsters.

© Yuan-kai Wang, Ya-xian Yan, Hyeun Bum Kim, Xianghong Ju, Song Zhao, Keshan Zhang, Saul Tzipori, and Xingmin Sun
*Correspondence to: Xingmin Sun; Email: Xingmin.Sun@tufts.edu
Submitted: 10/31/2014; Revised: 04/29/2015; Accepted: 05/14/2015
http://dx.doi.org/10.1080/21645515.2015.1052352
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
difficile toxins have been reported to be well tolerated and able to induce protective immunity in CDI in humans.22,30,31 However, chemical toxoiding requires establishing rigorous conditions to eliminate toxicity in the final drug product while minimizing any loss of immunogenicity. Genetic toxoiding has the advantage of avoiding chemical-treatment steps during vaccine bioprocess development. Therefore, recombinant polypeptides have been considered in several studies as potential vaccine candidates. In particular, RBDs of TcdA and TcdB have been evaluated for their ability to induce protective immunity.25,32-34

Recent studies have indicated that the N-terminal GT domain of TcdB can serve as an excellent immunogen.35,36 This notion was initially supported by our recent construction of a chimeric recombinant vaccine against TcdA and TcdB, i.e., cTxAB, in which the original RBD of a full-length TcdB was replaced with the corresponding portion of TcdA.37 cTxAB is protective in animal models. However, the cTxAB protein has a very low yield in B. megaterium, possibly because of the large size of the construct.

We also found that the neutralizing epitopes in TdBD are located in the N terminus37 in addition to other domains.32 Moreover, the N terminus of TcdB is more conserved than its RBD.38,39 In contrast, the RBD of TcdA has potent adjuvant activity, e.g., it has been reported that a TcdA receptor peptide fragment enhanced mucosal antibody responses in mice when co-administered with heterologous protective antigens.40 The RBD of TcdA has been used as an immunogen in several studies.28,34,40

In this study, we have generated a much simplified new chimeric protein, mTcd138, containing the GTD and CPD domains of TcdB and RBD of TcdA. mTcd138 was evaluated in mice and hamsters for its immunogenicity, and protection efficiency against CDI. Our data show that mTcd138 fusion protein may represent an alternative vaccine candidate for the protection against CDI.

Results

Construction and cytotoxicity testing of mTcd138

A construct encoding the mTcd138 fusion protein was generated that contains the GT and CPD domains of TcdB and the RBD of TcdA linked by a 4-aa sequence (Gly-Gly-Ser-Gly) (Fig. 1). Recombinant mTcd138 with a 6xHis-tag was expressed in B. megaterium and purified by Ni-affinity chromatography followed by ion exchange purification. The purification process yielded a highly pure product of about 138 kDa (Fig. 2A). Western blot analysis using specific antibodies against TcdA and TcdB verified the presence of TcdA and TcdB fragments (Fig. 2B, C). Approximately, 4–5 mg of mTcd138 was obtained from one liter of bacterial culture.

Residue toxic activity of fragments from receptor binding domain of TcdB has been reported at 100 μg/ml.31 In addition, trans-membrane domain of TcdB has also been reported to contribute to toxicity.42 To ensure that mTcd138 was atoxic, 2 amino acids, which have been reported to be the key residues involved in the GT activity,43,44 were mutated in the GT domain of TcdB (Fig. 1B). mTcd138 did not show detectable toxicity in in vitro (Fig. 3A). mTcd138 at a dose of 20 μg/ml did not cause visible cell morphological changes in Vero cells, while TcdA at 5 ng/ml or TcdB at 1 ng/ml led to complete cell rounding after 72-hour incubation (Fig. 3B). To further test in vivo toxicity of mTcd138, groups of mice were intraperitoneal (i.p.) challenged with TcdA, TcdB or mTcd138. All mice challenged i.p. with 100 ng of TcdA or TcdB died within 20 hours, while those challenged with 100 μg of mTcd138 survived (Fig. 3C) for 80 hours without any symptoms.

Immunization of mice with mTcd138 induces antibody and protects against both TcdA and TcdB

Immunization of mice with mTcd138 via i.p., intramuscular (i.m.) or intradermal (i.d.) routes induced potent but similar levels of IgG antibody responses against both TcdA and TcdB (Fig. 4A, B). Significant anti-TcdA and anti-TcdB IgG responses were induced in the first and second immunizations. mTcd138 immunization induced potent neutralizing antibodies against both toxins (Fig. 5), though neutralizing titers against TcdA were much higher than those against TcdB. More importantly, immunization of mice with mTcd138 provided full protection against systemic challenge of lethal dose of TcdA / TcdB (Fig. 6). All mTcd138-immunized mice survived the intraperitoneal injection of 200 ng of either TcdA or TcdB, whereas all the
placebo-immunized mice died from a i.p. injection with 100 ng of either toxin. Double mutant E. coli heat labile toxin (dmLT) was used in i.d. immunization as an adjuvant with an additional goal to stimulate mucosal response, however, no appreciable anti-TcdA or anti-TcdB IgA was detected in feces of mice immunized via the i.d. route (Data not shown).

**mTc138 vaccination protects mice from infection with an epidemic C. difficile strain**

We further evaluated the protection efficacy of mTc138 in a mouse model of CDI. After three immunizations via i.p., i.m. or i.d. routes, mice were challenged with $10^6$ spores of *C. difficile* UK6 (BI/NAP1/027). All mice in all PBS-immunized mice developed diarrhea (Fig. 7C) and weight loss (Fig. 7B). Approximately 60% mice died or became moribund and were euthanized by day 4 post-infection (Fig. 7A). In contrast, mTc138-immunized mice showed no appreciable signs of disease (Fig. 7B, C).

**Protective efficacy of mTc138 in the hamster model of C. difficile infection**

Hamsters are extremely sensitive to *C. difficile* infection, developing clinical signs of CDI rapidly, and die within 2 to 3 days of infection even at a very low dose of 100 spores. Therefore, hamster is an ideal animal model to test the strength of vaccines against CDI. To test the immunogenicity and protective response of mTc138, 2 groups of hamsters (*n = 8*) were i.p. immunized for 3 times at 14-day intervals with $10 \mu g$ of mTc138 or the same volume of PBS with alum as an adjuvant. Immunization of mTc138 induced rapid antibody responses against both toxins after first immunization (Fig 8A), and induced high-levels of anti-toxin antibodies similar to those in mice (Fig 4). Importantly, sera from immunized hamsters were able to neutralize TcdA and TcdB (Fig. 8B, C), although neutralizing titers against both toxins are lower than those of sera from mTc138 immunized mice (Fig 5). To test the strength of mTc138, 14 days after the third immunization, hamsters were i.p. injected with 30 mg/kg clindamycin followed by challenge at $2 \times 10^5$ *C. difficile* UK6 spores (lethal challenge dose is 100–1000 spores) 5 days later. All PBS-immunized hamsters developed diarrhea and died within 24–48 hours (Fig. 8D). All mTc138-immunized hamsters also developed diarrhea, however, they survived significantly longer (*P = 0.0075*) and 2 hamsters survived 7-day of monitoring period (Fig 8D).

**Discussion**

Both TcdA and TcdB are major *C. difficile* virulence factors. Vaccination targeting both toxins is necessary to provide the host full protection against CDI.

It was reported that TcdA is relatively well conserved, while TcdB has much variability, especially the RBD region. The N terminus encompassing the GTD and CPD domains is more conserved between historical and epidemic strains. In our previous study and consistent with others, we indicated that the N-terminus of TcdB was able to elicit a protective antibody response. In contrast, the RBD of TcdA has potent adjuvant activity, and has been used as vaccine candidates in several studies. Therefore, we hypothesized that a fusion protein containing the N-terminus of TcdB and RBD of TcdA would be immunogenic and sufficient to induce protection against both toxins.

Previously, we described the development of a chimeric recombinant protein vaccine (cTxAB) targeting both toxins. Here, we reported the construction of a much simpler immunogen targeting both TcdA and TcdB by fusing the glucosyltransferase and
cysteine proteinase domains of TcdB with the receptor binding domain of TcdA. This new construct is stable, and is easy to express and purify in large quantities. It is non-toxic and expressed in *B. megaterium*, a nonpathogenic and endotoxin-free production system. Immunization with mTcd138 fully protected mice against systemic challenge with lethal doses of toxins, and against infection with the hypervirulent strain *C. difficile* UK6. mTcd138 immunization also induced significant protective responses in hamsters. However, the protection in hamsters is not as impressive as in mice, which may partially due to the very high challenge *C. difficile* dose \(2 \times 10^5\) used in hamsters. Further evaluation of immunization does, routes and challenge dose of *C. difficile* spores will be pursued in both mice and hamsters in the near future.

Recently, Leuzzi et al. reported that the GT of TcdB, when expressed separately, was immunogenic and was able to induce neutralizing antibodies to TcdB. When expressed as a fusion with part of RBD of TcdA, however, the fusion protein could not induce anti-TcdB neutralizing antibodies.\(^{36}\) The fusion protein constructed by this group does not include the CPD domain of TcdB. The different outcomes of our study and that of Leuzzi et al., indicate that CPD is immunogenic and/or plays important roles in maintaining the native structure or epitope conformation of GTD. In fact, the importance of the CPD in eliciting anti-TcdB neutralizing antibodies was also documented by a recent report, in which a TcdB fragment (TxB4) containing RBD and TMD only induced half the amount of anti-TcdB neutralizing antibodies when compared to another TcdB fragment (TxB5) comprised of the CPD in addition to the TMD and RBD.\(^ {45} \)

**Materials and Methods**

**Preparation of *C. difficile* spores**

*C. difficile* UK6, an epidemic strain (kindly provided by Dale Gerding and Abraham L. Sonenshein)\(^ {46} \) was isolated in the United Kingdom. Sporulation of the *C. difficile* UK6 strain was induced in Clospore medium as described previously.\(^ {47} \) Briefly, an overnight 20 ml of *C. difficile* culture in Columbia Broth was inoculated into 500 ml of Clospore medium, and incubated for 1–2 weeks at 37°C in an anaerobic incubator. The spore suspension was centrifuged at 1000g for 10 min, and the pellet was

---

**Figure 4.** mTcd138 immunization via intraperitoneal (i.p.), intramuscular (i.m.) or intradermal (i.d.) route induces similar levels of antibody response. Groups of C57 BL/6 mice were immunized 3 times at 14-day intervals via i.p., i.m. or i.d. route with 10 \(\mu\)g of mTcd138 in the presence of alum (i.m. and i.p.) or double mutant *E.coli* heat labile toxin (dmLT) (i.d.) as an adjuvant. Sera were collected, and anti-TcdA (A) or anti-TcdB (B) IgG titers measured by standard ELISA.

**Figure 5.** Serum anti-toxin neutralizing titers of the mTcd138-immunized mice (i.p.). Vero cells were used to determine in vitro neutralizing activities of sera. The neutralizing titer is expressed as the maximum dilution of the sera that inhibits cell rounding caused by toxin at a given concentration. This given concentration is the minimum toxin dose causing cell rounding after a 16 h of toxin exposure, i.e., 2.5 and 0.1 ng/ml for TcdA and TcdB, respectively.

**Figure 6.** mTcd138 immunization protects mice against systemic toxin challenge. Kaplan-Meier survival plot of mTcd138-immunized (i.p.) or control mice challenged with lethal dose of TcdA or TcdB (i.p.).
washed 5 times with sterile water and suspended in 10 ml of ddH₂O. The spore suspension was heated at 60°C for 20 min to kill vegetative cells and stored at 4°C. The spore concentration was determined by serial dilution on TCCFA or BHI plates.48

Expression of recombinant fusion protein mTcd138 in *Bacillus megaterium*

Genes encoding TcdA and TcdB from *C. difficile* VPI10463 were previously cloned in an *E.coli-B. megaterium* shuttle vector pHs1525 and expressed in *B. megaterium*.49 Recombinant TcdA and TcdB were expressed in *B. megaterium* and purified as described previously.49

To generate mTcd138, the DNA sequences from *C. difficile* VPI 10463, encoding the glucosyltransferase (GTD 1–543 aa) with 2 amino acid mutations (W102A and D288N) and cysteine proteinase (CPD, 543–767) domains of TcdB and receptor binding domain (RBD) of TcdA were bridged with a linker (ggt ggc tct ggt) sequence, synthesized by Geneart (Germany) and cloned between the BsrGI and EagI sites of the vector pHis1525. mTcd138 was expressed in *B. megaterium* and purified as described previously.49

Cytotoxicity of mTcd138 in cells

Cytotoxicity of the toxins was assayed as described previously.49 Briefly, vero cells in 96-well plates were exposed to TcdA/TcdB or mTcd138 at different concentrations. MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide] assays were used to determine the toxin or mTcd138 cytotoxicity. After 72 h of treatment, 10 μl of MTT (5 mg/ml) was added to each well, and were incubated for additional 4 h at 37°C, followed by dissolving the formed formazan 0.4 N HCl in absolute isopropanol. The absorbance was recorded at 570 nm. Cell viability was defined as the percentage of survived cells in comparison with the non-treated cells.

Cytotoxicity of mTcd138 in mice

Female C57 BL/6 mice (n = 10) were i.p. challenged with 100 ng TcdA/ TcdB or 100 μg mTcd138 per mouse. Mouse survival was monitored and analyzed by Kaplan-Meier survival analysis.
Mouse immunization and mouse model of *C. difficile* infection

Female C57/BL6 mice were housed under the same conditions. All studies followed the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Tufts University Institutional Animal Care and Use Committee under the protocol #G2012-70. Mice (n = 10) were immunized 3 times at 14-day intervals via i.p., intramuscular (i.m.) or intradermal (i.d.) routes with 10 μg of mTcd138 in PBS along with alum (i.m. and i.p.) or double mutant *E. coli* heat labile toxin (dmLT) at 5 μg/mouse (i.d.) as adjuvants. dmLT, an adjuvant for mucosal immunization, was used in i.d. immunization with an additional goal to stimulate mucosal response. Lyophilized dmLT was manufactured at Walter Reed Army Institute for Research (Silver Spring, MD, BPR-928-00, Lot No, 1575). Control mice received PBS with alum. Sera were collected. Immunized or control mice were pretreated with an antibiotic cocktail following with *C. difficile* spore infection via oral gavage as described previously.14,15 Fourteen days after the third immunization, mice were challenged with $10^6$ *C. difficile* UK6 spores.

Hamster immunization and challenge with *C. difficile*

Golden Syrian female hamsters used in the experiments were housed in cages individually under the same conditions. All studies followed the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Tufts University Institutional Animal Care and Use Committee under the protocol #G2014-90.

Hamsters were i.p. immunized with 10 μg of mTcd138 in 100 μl of PBS with alum as an adjuvant for 3 times at 14-days intervals. Control hamsters were immunized with same volume of PBS plus alum. Sera were collected, and anti-TcdA/TcdB IgG titers were determined by ELISA. Two weeks after third immunization, hamsters were i.p. administered with one dose of clindamycin at 30 mg/kg followed by oral challenge with $2 \times 10^5$ *C. difficile* UK6 spores 5 days later. The hamsters were monitored for 7 days for diarrhea and other disease symptoms.

Antibody titers and neutralizing assays

Antibody titers were measured using a standard ELISA against purified recombinant wild-type TcdA or TcdB. Vero cells were used to assess neutralizing activities of serum samples. The neutralizing titer is defined as the maximum dilution of the samples that blocks cell rounding caused by toxin at a given concentration. This given concentration is the minimum dose of the toxin that causes all cells to round after a 16-h exposure to the toxin, i.e., ca 2.5 and 0.1 ng/ml for TcdA and TcdB, respectively.

Statistical analysis

Data were analyzed by Kaplan-Meier survival analysis using Prism statistical software. Results are expressed as means ± standard errors of means.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Hanping Feng (University of Maryland) for providing *B. megaterium* strains expressing wild-type and mutant TcdA/TcdB. We thank Abraham L. Sonenschein, Giovanni F. Widmer, Diane Schmidt (Tufts University) and Gary Ostooff (University of Massachusetts Medical School) for critical comments of the manuscript. We also thank Weijia Nie for technical assistance.

Funding

This work was supported by NIH grant K01DK092352 (X. Sun), Tufts Collaborates 2013_V330421 (X. Sun), Tufts Collaborates 2014_V330423 (X. Sun), Tufts Innovation Institute Award 2014_V330427 (X. Sun) and partially by NIH grant AI088748 (S. Tzipori/H. Feng).

Authors’ Contributions

X. Sun conceived and designed the experiments. Y. Wang, H. B. Kim, X. Ju, S. Zhao, K. Zhang and X. Sun performed the experiments. Y. Wang, Y. Yan and X. Sun analyzed the data. X. Sun, Y. Wang, Y. Yan and S. Tzipori contributed to the writing of the manuscript. All authors read and approved the final manuscript.

References

1. Rebeaud F, MF Bachmann. Immunization strategies for *Clostridium difficile* infections. Expert Rev Vaccines. 11(4); p. 469-79; PMID:22551032; http://dx.doi.org/10.1586/erv.12.18
2. O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of *clostridium difficile*-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007; 28(13); p. 1219-27; http://dx.doi.org/10.1016/j.ice.2008.01.011
3. Pruitt RN, DB Lacy. Toward a structural understanding of *C. difficile* glucosylating toxins: the ABCD model. Trends Microbiol. 2008; 16(5); p. 222-9; http://dx.doi.org/10.1016/j.tim.2008.01.011
4. Pruitt RN, DB Lacy. Toward a structural understanding of *C. difficile* glucosylating toxins: the ABCD model. Trends Microbiol. 2008; 16(5); p. 222-9; http://dx.doi.org/10.1016/j.tim.2008.01.011
5. Jank T, K Akotoye. Structure and mode of action of *clostridium difficile* toxins: the ABCD model. Trends Microbiol. 2008; 16(5); p. 222-9; http://dx.doi.org/10.1016/j.tim.2008.01.011
6. Faloona OK, DB Lacy. Toward a structural understanding of *C. difficile* glucosylating toxins: the ABCD model. Trends Microbiol. 2008; 16(5); p. 222-9; http://dx.doi.org/10.1016/j.tim.2008.01.011
7. McDonald LC, Coignard B, Dubberke E, Song X, Hori K, Normand M; Canadian Nosocomial Infection Surveillance Working Group. Recommendations for surveillance of *Clostridium difficile*-associated disease. Infect Control Hosp Epidemiol, 2010; 31(5); p. 431-55; PMID:20379191; http://dx.doi.org/10.1086/651706
8. Cohen SH, Gerdin DN, Johnson S, Kelly CP, Loo VG, McDonald LG, Pepin J, Wilson MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection Control Hosp Epidemiol. 2010; 31(5); p. 431-55; PMID:20379191; http://dx.doi.org/10.1086/651706
9. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Siers P, Gorbach S; OPT-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 12(4); p. 281-9; PMID:22321770
10. Tonna I, PD Welby. Pathogenesis and treatment of *Clostridium difficile* infection. Postgrad Med J. 2005.
11. Barbut F, Kent SA, O’Leary KJ, Manganese MM, Sambo SP, Peterson LR, Gerding DN. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassays. Ann Intern Med. 2001. 135(6): p. 434-8; http://dx.doi.org/10.1056/ANNI010576:00392-3

15. Johnson S, Kent SA, O’Leary KJ, Merrigan MM, Sambo SP, Peterson LR, Gerding DN. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassays. Ann Intern Med. 2001. 135(6): p. 434-8; http://dx.doi.org/10.1056/ANNI010576:00392-3

18. van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Klonapen P, van Belkum A, Monath TP, Thomas WD Jr. Serum antitoxin response induced by a two-component Clostridium difficile vaccine and serum immunoglobulin. 2011. 12.064

20. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel J, Mehta H, Kleanthous H. Systemic antibody responses induced by a two-component Clostridium difficile vaccine and serum immunoglobulin. 2011. 12.064

21. Kyne L, Warner M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet. 2001. 357(9215): p. 198-9; http://dx.doi.org/10.1016/S0140-6736(00)03952-3

26. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean AP, van der Vorm ER, Weel J, van Rheenen C, Danforth JA, van Belkum A. Serum antitoxin response induced by a two-component Clostridium difficile vaccine and serum immunoglobulin. 2011. 12.064

29. Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic antibody responses induced by intranasal immunization with the nontoxic binding domain of Clostridium difficile toxin A. Infect Immun, 1999. 67(10): p. 5124-32

35. Jin K, Wang S, Zhang C, Xiao Y, Lu S, Huang Z. Production, purification, and characterization of a recombinant α toxin derivative of Clostridium difficile. PLoS Pathog. 6(8): p. e1001061; http://dx.doi.org/10.1371/journal. ppat.1001061

39. Ward SJ, Douce G, Dougan G, Wren BW. Local and systemic antibody responses induced by intranasal immunization with the nontoxic binding domain of Clostridium difficile toxin A. Infect Immun, 1999. 67(10): p. 5124-32

40. Brun P, Scarpa M, Grillo A, Pal G, Mengoli C, Zecconi A, Spigaglia P, Magistrantoni P, Castagnoli P, Ichie A, et al. Comparison of C. difficile toxin A and B in hamsters. J Med Microbiol. 2008. 57 (Pt 6): p. 725-31; http://dx.doi.org/10.1099/jmm.0.47765-0

41. Zemljic M, Rupeik M, Scarpa M, Anderligh D, Pal G, Pal G, etc. A novel approach to a recombinant toxin A vaccine against Clostridium difficile. Microbiology, 2013. 159(Pt 7): p. 1254-66; http://dx.doi.org/10.1099/mic.0.05927-0

42. Donald RG, Flint M, Kalyan N, Johnson E, Winko S, Kocis A, Heilmann C. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A elicits protective immunity in a mouse model of experimental Clostridium difficile diarrhoea. J Med Microbiol. 2009. 58 (Pt 6): p. 477-80; http://dx.doi.org/10.1099/jmm.0.002198-0

43. Teichert M, Tarpe H, Schoneauff J, Just I, Gerhard R. Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects. Infect Immun, 2006. 74(9): p. 6066-10; http://dx.doi.org/10.1128/IAI.00545-06

44. Busch C, Hofmann F, Selzer J, Munro S, Jeckel D, Akories K. A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins. J Biol Chem, 1999. 274(19): p. 19566-72; http://dx.doi.org/10.1074/jbc.273.31.19566

45. Maynard-Smith M, Aher M, McGland J, Nugent P, Ling R, Denton H, Coson R, Landon J, Roberts A, Sander A, et al. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin neutralising immune response. Vaccine, 2013. 31(19): p. 2995-3002; http://dx.doi.org/10.1016/j.vaccine.2013.10.099

46. Kjellgren G, Thompson A, Johnson S, Brazier J, Kajiwara E, Pepein J, Frost EH, Savelkoul P, Nicholson B, van den Bergh RJ, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulse-field gel electrophoresis, PCR-rhibotyping, pulsed-field gel electrophoresis, PCR-rhibotyping, multilocus enzyme electrophoresis, and phenotypic analysis. J Clin Microbiol, 2004. 42(2): p. 618-20; http://dx.doi.org/10.1128/JCM.01484-07

47. Peter J, VS Springbooth, SA Sattar. Clospore: a liquid medium for producing high titers of partially purified spores of Clostridium difficile. J AOAC Int, 2011. 94 (2): p. 618-20

48. Soj GA, Al Sonnenheim. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenoenoxylic acid, a bile acid. J Bacteriol, 2010. 192(19): p. 4983-90; http://dx.doi.org/10.1128/ JBC.00610-10
49. Yang G, Zhou B, Wang J, He X, Sun X, Nie W, Tzipori S, Feng H. Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol, 2008. 8: p. 192; http://dx.doi.org/10.1186/1471-2180-8-192

50. Lee SW, Picking, Tzipori. The immune response of two microbial antigens delivered intradermally, sublingually, or the combination thereof. Microbes Infect 2014; 16(9):796-803; PMID:25111827; http://dx.doi.org/10.1016/j.micinf.2014.07.013

51. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. A mouse model of Clostridium difficile-associated disease. Gastroenterology, 2008. 135(6): p. 1984-92; http://dx.doi.org/10.1053/j.gastro.2008.09.002
52. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. Mouse relapse model of Clostridium difficile infection. Infect Immun, 2011. 79(7): p. 2856-64; http://dx.doi.org/10.1128/IAI.01336-10